Your browser doesn't support javascript.
loading
Release Mechanisms of Amorphous Solid Dispersions: Role of Drug-Polymer Phase Separation and Morphology.
Yang, Ruochen; Zhang, Geoff G Z; Zemlyanov, Dmitry Y; Purohit, Hitesh S; Taylor, Lynne S.
Afiliação
  • Yang R; Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, 47907, USA.
  • Zhang GGZ; Drug Product Development, AbbVie Inc., North Chicago, IL, 60064, USA.
  • Zemlyanov DY; Birck Nanotechnology Center, Purdue University, West Lafayette, IN, 47907, USA.
  • Purohit HS; Drug Product Development, AbbVie Inc., North Chicago, IL, 60064, USA. Electronic address: hitesh.purohit@abbvie.com.
  • Taylor LS; Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, 47907, USA. Electronic address: lstaylor@purdue.edu.
J Pharm Sci ; 112(1): 304-317, 2023 01.
Article em En | MEDLINE | ID: mdl-36306863
Formulating poorly soluble molecules as amorphous solid dispersions (ASDs) is an effective strategy to improve drug release. However, drug release rate and extent tend to rapidly diminish with increasing drug loading (DL). The poor release at high DLs has been postulated to be linked to the process of amorphous-amorphous phase separation (AAPS), although the exact connection between phase separation and release properties remains somewhat unclear. Herein, release profiles of ASDs formulated with ritonavir (RTV) and polyvinylpyrrolidone/vinyl acetate (PVPVA) at different DLs were determined using surface normalized dissolution. Surface morphologies of partially dissolved ASD compacts were evaluated with confocal fluorescence microscopy, using Nile red and Alexa Fluor 488 as fluorescence markers to track the hydrophobic and hydrophilic phases respectively. ASD phase behavior during hydration and release of components were also visualized in real time using a newly developed in situ confocal fluorescence microscopy method. RTV-PVPVA ASDs showed complete and rapid drug release below 30% DL, partial drug release at 30% DL and no drug release above 30% DL. It was observed that formation of discrete drug-rich droplets at lower DLs led to rapid and congruent release of both drug and polymer, whereas formation of continuous drug-rich phase at the ASD matrix-solution interface was the cause of poor release above certain DLs. Thus, the domain size and interconnectivity of phase separated drug-rich domains appear to be critical factors impacting drug release from RTV-PVPVPA ASDs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros / Pirrolidinas Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros / Pirrolidinas Idioma: En Ano de publicação: 2023 Tipo de documento: Article